Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals
On the sidelines of the BIO-Europe partnering conference, held in Cologne, Germany, Dr Joerg Moeller, head of development for Bayer's pharmaceuticals division, and Evotec CEO Dr Werner Lanthaler tell Scrip why their partnerships work and what challenges they have overcome to create short-term syndicated businesses with specific therapeutic focuses.
You may also be interested in...
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
Medtech Insight's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – in vitro diagnostics and medical devices – and then categorized by type – acquisition, alliance, or financing. This month’s column covers deals announced in September 2021. Data provided by Biomedtracker.